Advaxis, Inc.

  • ID: 4244571
  • Company Profile
  • 30 pages
  • Dquester
  • Advaxis Inc
1 of 3
Advaxis is a clinical-stage biotechnology company focusing on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies that enlist the body’s own immune system to fight cancer. Axalimogene filolisbac (AXAL) is the company’s lead product candidate which has completed phase 2 study and has received United States Food and Drug Administration (FDA) orphan drug designation for three cancers: cervical, head and neck, and anal cancer. It has received European Medicines Agency (EMA) orphan drug designation for anal cancer.

The company is also evaluating ADXS-PSA (phase 1/2) for prostate cancer and ADXS-HER2 (phase 1) for the treatment of human epidermal growth factor receptor expressing cancers, including human and canine osteosarcoma. Advaxis has a few clinical trial collaboration agreements with Merck & Co. It also has a licensing agreement with Global BioPharma Inc.; co-development and commercialization agreement with Especificos Stendhal SA de CV; and collaboration agreement with Amgen Inc. For the year ended October 31st 2016, Advaxis reported revenues of $4.0 million. Advaxis was founded in 2002 and is based in Princeton, New Jersey.

Whether Advaxis, Inc. is your investment target, a potential business partner, a business prospect, a supplier or a rival - this Company Quest Report packages all the key aspects from which Advaxis, Inc. can be looked at. Vital details related to the company’s operations, history, growth strategy, financial performance, and competitive position are thoroughly studied and captured in this report, along with a SWOT analysis.
Note: Product cover images may vary from those shown
2 of 3

1. COMPANY OVERVIEW

  • Business summary
  • Products and services
  • Growth history/key milestones
  • Ownership and management
  • Recent developments

2. BUSINESS DETAILS

  • Business segment details
  • Subsidiaries and affiliates
  • Alliances and partnerships

3. STRATEGY

  • Growth strategy
  • M&A history

4. FINANCIAL AND OPERATIONAL PERFORMANCE

  • Company performance - last 5 years and last 5 quarters
  • Segmental performance - last 5 years and last 5 quarters
  • Trading performance

5. COMPETITIVE LANDSCAPE

  • Key competitors
  • Market share/positioning
  • Summary profiles/service comparison of key competitors
  • Comparative stock chart
  • Comparison of market cap, sales & profitability growth with peers

6. SWOT ANALYSIS

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll